EUCTR2008-001443-19-FR进行中（未招募）1 期
Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subjects with moderate to severe chronic plaque psoriasis
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females aged 18 to 60 years (inclusive).
- •2. For female subjects, a woman of childbearing potential must:
- •have a negative serum pregnancy test at screening and a negative urine pregnancy test at randomization (before the first study drug intake).
- •agree to use two methods of contraception from the screening visit until 2 months after study drug discontinuation.
- •Of the two contraceptive methods, one must be from Group 1, and one must be from Group 2, defined as follows:
- •Group 1: Oral, implantable, transdermal or injectable hormonal contraceptives, intrauterine devices, female sterilization (tubal ligation), or partner’s sterilization (vasectomy). If a hormonal contraceptive will be chosen from this group, it must have been taken for at least 1 month prior to randomization (i.e., Visit 2).
- •Group 2: Condoms, diaphragm or cervical cap, all in combination with spermicide.
- •Abstention and rhythm are not acceptable methods of contraception.
- •A woman is considered to be of childbearing potential unless she meets at least one of the following criteria:
- •Previous bilateral salpingo-oophorectomy, or hysterectomy.
- •Premature ovarian failure confirmed by a specialist gynecologist.
- •Age > 50 years and not treated with any kind of hormone replacement therapy (HRT) for at least 2 years prior to screening, with amenorrhea for at least 24 consecutive months prior to screening, and a serum follicle-stimulating hormone (FSH) level of > 40 IU/L at screening.
- •Age > 55 years and treated with HRT prior to screening with appropriate medical documentation of spontaneous amenorrhea for at least 24 consecutive months.
- •3. Moderate to severe plaque psoriasis with body surface area (BSA) involvement > 10% and PASI score > 10, which is stable for at least 3 months, requires systemic treatment, and for which treatment in a placebo-controlled study of an investigational drug can be justified.
- •4. Signed informed consent form prior to initiation of any study-mandated procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Breast-feeding women.
- •2. Generalized erythrodermic, generalized pustular psoriasis (von Zumbusch), guttate, and palmo-plantar psoriasis.
- •3. Treatment with:
- •Ultraviolet B (UVB) therapy, psoralen-ultraviolet-light (PUVA) therapy and topical treatments for psoriasis other than emollients within 1 month prior to start of study drug.
- •Oral retinoids, methotrexate, cyclosporine and systemic corticosteroids within 1 month prior to start of study drug.
- •Approved immunosuppressive or immunomodulatory biological agents (e.g., infliximab, etanercept, alefacept, efalizumab, adalimumab) within 3 months prior to start of study drug.
- •Investigational non lymphocyte-depleting biological agents (recombinant proteins or monoclonal antibodies) within 6 months prior to start of study drug or lymphocyte-depleting biological agents at any point in time.
- •Other systemic immunosuppressive drugs (e.g., mycoophenolate acid, sirolimus) within 3 months prior to start of study drug.
- •Treatment with another investigational drug within 3 months prior to start of study drug.
- •Vaccination with live vaccines within 3 month prior to start of study drug.
- •Treatment with ß-blockers, diltiazem, verapamil, digoxin, amiodarone, and lithium (for any indication) within 1 month prior to start of study drug.
- •4. Subjects currently treated for autoimmune disorders other than psoriasis.
- •5. Ongoing bacterial, viral or fungal infection (with the exception of onychomycosis and dermatomycosis), positive hepatitis B surface antigen or hepatitis C antibody tests.
- •6. Congenital or acquired severe immunodeficiency or known human immunodeficiency virus (HIV) infection.
- •7. History or presence of malignancy (except for basal or squamous cell skin lesions which have been surgically excised), lymphoproliferative disease and subjects who received total lymphoid irradiation or bone marrow transplantation.
- •8. Poorly controlled type I or II diabetes.
- •9. History or presence of macular edema or diabetic retinopathy (as confirmed by fundoscopy within 28 days prior to randomization).
- •10. Any of the following cardiovascular conditions:
- •Resting heart rate (HR) < 60 bpm.
- •PR > 180 ms.
- •Symptomatic ischemic heart disease.
- •History of valvular heart disease.
- •History of heart failure.
- •History or presence of rhythm disorders (e.g., sino atrial heart block, second degree atrioventricular [AV] block, third degree AV-block, sick sinus syndrome, symptomatic bradycardia, atrial flutter or atrial fibrillation) or subjects who receive anti-arrhythmic therapy.
- •History of syncope.
- •Arterial hypertension uncontrolled by medications.
- •11. Any of the following pulmonary conditions:
- •Moderate and severe bronchial asthma or chronic obstructive pulmonary disease (COPD) stage II–IV (i.e., forced expiratory volume in 1 second [FEV1] < 70%).
- •History of pulmonary fibrosis (scarring of the lung), pulmonary Langerhans’ cell histiocytosis.
- •History of tuberculosis, or positive chest X-ray at screening or within the previous 3 months, suggestive of active or latent tuberculosis.
- •12. Abnormal liver function tests as defined by persisting elevations of alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT) or aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) or total bilirubin > 2-fold the upper limit of the normal range (ULN).
- •13. Any of the following abnormal laboratory values:
- •Hemoglobin (Hb) < 10g/dL.
- •White blood cells (WBC) count <
研究者
相似试验
进行中（未招募）
不适用
Multicenter, randomized, double-blind, placebo-controlled, study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn?s Disease - DSC/06/2357/23Crohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-000189-19-ITITALFARMACO80
尚未招募
Unknown
Multicenter, randomized, double-blind, placebo-controlled study toassess the effects of enavogliflozin on outcomes in patients withfunctional tricuspid regurgitation and preserved left ventricularejection fractioDiseases of the circulatory systemKCT0008631Asan Medical Center588
进行中（未招募）
不适用
Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy (quality of life) and safety of the standardized mistletoe extract PS76A2 during chemotherapy and follow-up in patients with breast cancerFemale patients with breast cancer shortly after surgery [pTNM classification: pT1-T4, pN0-N+ (0-9 positive lymph nodes), pM0] qualified for adjuvant chemotherapy according to FEC scheme as standard of careMedDRA version: 13.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-000841-36-PLRottapharm Madaus, Madaus GmbH320
进行中（未招募）
不适用
Assessment of efficacy of CR8020 and CR6261, monoclonal antibodies, against influenza infectioInfluenzaEUCTR2013-003341-41-SECrucell Holland B.V.296
进行中（未招募）
不适用
Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosisrelapsing-remitting multiple scelorsisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-006786-92-HUActelion Pharmaceuticals Ltd400